Skip to main content
OpenTrials
Completed

NCT Number: NCT00857350

The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses:

1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%. 2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Positive Blood-Borne Infections Chemically-Induced Disorders Communicable Diseases Genital Diseases HIV Infections HIV Seropositivity Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections Mental Disorders Narcotic-Related Disorders Opioid Agonist Treatment Opioid Dependence Opioid-Related Disorders RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Substance-Related Disorders Urogenital Diseases Virus Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Yale University Hospital

New Haven, Connecticut, 06511, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HIV+
  • Opioid dependent
  • Receiving methadone or buprenorphine for at least one month

Exclusion criteria

  • age < 18 years
  • current dementia;
  • inability to read or understand English
  • inability to provide written informed consent

Treatment and study plan

Primary outcomes

  1. HIV drug resistance

    Time frame: Cross sectional

Secondary outcomes

  1. Illicit drug use

    Time frame: 6 months

  2. HIV transmission risk behaviors

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Important dates

Study start
2008
Primary completion
2010
Study completion
2012
First posted
Mar 6, 2009
Registry last updated
Jul 22, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.